Highlights
- Monash IVF Group offers reproductive and fertility services across Australia
- In 1HFY24, MVF witnessed 21.7% YoY rise in the revenue to AUD 125.7 million
- Argo Investments Limited has the highest stake in the company with a shareholding of ~5.13%
Monash IVF Group Limited (ASX: MVF) specialises in developing assisted reproductive technologies and prenatal diagnostics. The company provides a variety of specialized diagnostic services, including obstetric and gynaecological ultrasounds, as well as fertility treatments.
In the first half of the financial year 2024 (1HFY24), the company recorded a 21.7% YoY increase in its revenue to AUD 125.7 million and 18.7% YoY growth in underlying NPAT to AUD 15 million. Meanwhile, underlying EBITDA jumped 20% YoY to AUD 32.2 million.
The performance during the six months was driven by increased market share and positive industry growth. 1HFY24 marked the second consecutive half in which the company posted revenue and underlying EBITDA growth of 20% or more.
Top 10 shareholders of MVF
The top 10 shareholders of MVF have around 32.06% shareholding in the company, while the top four have 19.84% shareholding. Argo Investments Limited and Tribeca Investment Partners Pty Ltd. have the highest stake in the company with a shareholding of ~5.13% and ~5.00%, respectively.

Recent business update
Through an ASX update dated 4 March 2024, the company informed shareholders about the completion of the acquisition of Fertility North Holdings Pty Ltd. Fertility North offers fertility services to Perth’s northern suburbs. With this transaction, the company expands its presence in the fast-growing Perth market.
On 1 March 2024, the company informedshareholders that it was added to the S&P/ASX 200 index, with effect from 18 March 2024.
Outlook
In FY24, the company expects to deliver underlying NPAT of AUD 29-30 million. The forecast excludes contributions from the recently acquired entity, Fertility North.
In 2HFY24, the company expects earnings and revenue growth to be fuelled by multiple factors – continuous improvement in the ultrasound business, beginning contributions from new day hospital operations, the impact of the PIVET Medical Centre acquisition and developments in the operations in South-East Asia.
The company is committed to attracting suitable fertility specialists, investing in infrastructure and expanding its network.
Share performance of MVF
MVF shares closed 3.66% lower at AUD 1.315 apiece on 26 June 2024. With this, in the last one year, MVF’s share price has increased by almost 14.35%, and in the last three months, it has declined by 9.62%.
The 52-week high of MVF is AUD 1.53, recorded on 24 April 2024, and the 52-week low is AUD 1.105, recorded on 7 July 2024.

MVF Daily Technical Chart, Source: EODHD/Others
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 26 June 2024. The reference data in this report has been partly sourced from EODHD/Others.
Disclaimer
This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.